220
Participants
Start Date
June 24, 2019
Primary Completion Date
May 12, 2026
Study Completion Date
May 12, 2026
TNB-383B
Intravenous (IV) Injection
Universitaetsklinikum Hamburg-Eppendorf /ID# 239636, Hamburg
Wake Forest Univ HS /ID# 238787, Winston-Salem
University of North Carolina /ID# 238685, Chapel Hill
Levine Cancer Institute /ID# 238786, Charlotte
Duplicate_Universitaetsklinikum Muenster /ID# 239637, Münster
Universitaetsklinikum Koeln /ID# 239676, Cologne
Wisconsin Medical Center /ID# 238684, Milwaukee
Washington University-School of Medicine /ID# 238681, St Louis
Tulane University School of Medicine /ID# 242322, New Orleans
University of California San Francisco (UCSF) - Parnassus Heights /ID# 238680, San Francisco
Mayo Clinic - Rochester /ID# 238683, Rochester
Mt Sinai /ID# 242317, New York
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 244831, New York
Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 239638, Dresden
Collaborators (1)
AbbVie
INDUSTRY
TeneoOne Inc.
INDUSTRY